Overview

Double-Blind, Placebo-Controlled Study of Two Doses of EPA-E in Patients With Non Alcoholic Steatohepatitis (NASH)

Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
This is a controlled study to determine the effectiveness and safety of ethyl icosapentate (EPA-E) in the treatment of adult patients with non-alcoholic steatohepatitis (NASH).
Phase:
Phase 2
Details
Lead Sponsor:
Mochida Pharmaceutical Company, Ltd.
Treatments:
Eicosapentaenoic acid ethyl ester